On May 5, 2022 Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, reported that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Company’s lead drug candidate, batiraxcept (Press release, Aravive, MAY 5, 2022, View Source [SID1234613756]). Senior management will also provide updates on Aravive’s clinical development programs. The event will take place on May 11, 2022, from 8:00 am ET to 12:00 pm ET and will include a live and archived webcast at: View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The anticipated KOL Symposium schedule (all times are ET):
8:50 am – 9:00 am Opening Remarks
Gail McIntyre, Ph.D.; Aravive CEO and Director
9:00 am – 9:30 am Overview of the TAM Kinases:
Amato Giaccia, Ph.D.; Aravive Founder and Director Director, MRC Oxford Institute for Radiation Oncology Jack, Lulu and Sam Wilson Professor of Radiation Oncology, Emeritus, Stanford University
9:30 am – 10:00 am Batiraxcept in PROC:
Katherine Fuh, M.D., Ph.D.; Gynecologic Oncologist & Associate Professor Division of Gynecologic Oncology, Washington University, Siteman Cancer Center
10:00 am – 10:30 am Batiraxcept in ccRCC:
Brian Rini, M.D.; Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center & Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center
10:30 am – 11:00 am Batiraxcept in Pancreatic Adenocarcinoma:
Paul Oberstein, M.D., M.S.; Associate Professor of Medicine and Director of Gastrointestinal Medical Oncology, Perlmutter Comprehensive Cancer Center, NYU Langone Health
11:00 am – 11:15 am Program Updates
11:15 am – 12:00 pm Panel Discussion and Q&A